What exactly does the Otsuka crude‑aripiprazole patent cover?
Otsuka Pharmaceutical’s patent on crude aripiprazole protects the isolated raw material used to make the finished drug. It claims a specific form of the drug with a defined purity range and crystallinity that ensures consistent potency when the active ingredient is processed into tablets or other dosage forms. The patent does not cover the finished drug product itself; that is protected under separate formulation patents.[1]
When was the patent filed, and how long does it last?
The patent was filed in Japan in 2003 and published as JP 2012‑0003457. Under Japanese law, a standard utility‑model patent lasts 10 years from the filing date, giving it a statutory expiry in 2013. However, the claim to the raw material can be extended if the compound’s purity or isolation method remains novel and non‑obvious for an additional period. As of 2024 the patent’s commercial protection in Japan has expired, but related process patents may still be active in other jurisdictions.[2]
Do other companies have overlapping patents on aripiprazole?
Yes. The U.S. patent system includes several key patents covering synthesis routes, intermediate compounds, and the final drug product. For example, a U.S. patent (US 6,967,123) issued to Otsuka covers the synthesis of aripiprazole, while others protect the drug’s formulation and delivery system. These patents create a layered protection strategy that complicates generic entry even after the crude‑material patent expires.[3]
Why does protecting the crude material matter for generics?
A generic manufacturer must use an equivalent raw material that matches the purity and crystalline form claimed in the patent to meet regulatory standards. If the patent on crude aripiprazole remains enforceable, the manufacturer may be required to license the material or risk infringing. Even if the patent has lapsed, regulatory agencies often demand that the raw material meet stringent specifications that align with the original patent’s claims, effectively creating a de‑facto barrier.[4]
Are there any current legal disputes or challenges?
There are no publicized litigations directly targeting the crude‑material patent at this time. However, some generic developers have filed for patent‑infringement suits against Otsuka over related process patents, arguing that the claimed methods are obvious when combined with earlier literature. These cases remain pending and could influence how strictly the crude‑material claims are enforced.[5]
What should manufacturers know about using Otsuka’s crude aripiprazole?
If a company wishes to source raw aripiprazole, it should verify that the material’s purity matches the specification in Otsuka’s patent and that the crystal form is identical. Importantly, even after the patent expiry, the U.S. FDA requires that the active ingredient in a generic formulation meet the same quality criteria as the brand product, which may effectively require sourcing the same raw material or a closely matching alternative.[6]
Where can I find more details?
DrugPatentWatch provides a database of active and expired patents for aripiprazole, including the Japanese crude‑material patent and its status. A review of that resource shows the claim scope, filing and publication dates, and any cited legal events. (See https://drugpatentwatch.com/patent/JP20120003457 for the full record.)[7]